阿霉素和丝裂霉素C作为晚期乳腺癌的初始化疗药物。

Adriamycin and mitomycin C as initial chemotherapy for advanced breast cancer.

作者信息

Amiel S A, Stewart J F, Earl H M, Knight R K, Rubens R D

出版信息

Eur J Cancer Clin Oncol. 1984 May;20(5):631-4. doi: 10.1016/0277-5379(84)90008-7.

Abstract

Adriamycin and mitomycin C in combination have been tested in the treatment of advanced breast cancer. In an initial pilot study 11 heavily pretreated patients received mitomycin C alone and 2 (18%) achieved partial responses. Subsequently, 27 patients who had not received prior chemotherapy for advanced breast cancer were treated with adriamycin 40 mg/m2 + mitomycin C 10 mg/m2 i.v. every 3 weeks. Six (22%) achieved complete and 10 (37%) achieved partial responses, giving an objective regression frequency of 59%. The median duration of response was 37 weeks (range 8-55+ weeks).

摘要

已对阿霉素与丝裂霉素C联合用药治疗晚期乳腺癌进行了测试。在一项初步的试点研究中，11例经过大量前期治疗的患者单独接受丝裂霉素C治疗，2例（18%）获得部分缓解。随后，27例未接受过晚期乳腺癌前期化疗的患者接受阿霉素40mg/m² + 丝裂霉素C 10mg/m²静脉注射，每3周一次。6例（22%）获得完全缓解，10例（37%）获得部分缓解，客观缓解率为59%。缓解的中位持续时间为37周（范围8 - 55 +周）。